Preclinical studies of novel targeted therapies.
The bone marrow (BM) milieu confers drug resistance in multiple myeloma (MM) cells to conventional therapies. Novel biologically based therapies are therefore needed. Preclinical studies have identified and validated molecular targeted therapeutics in MM. In particular, recognition of the biologic significance of the BM microenvironment in MM pathogenesis and as a potential target for novel therapeutics has already derived several promising approaches. Thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade) are directed not only at MM cells but also at the BM milieu and have moved rapidly from the bench to the bedside and United States Food and Drug Administration approval to treat MM.
Hideshima
Teru
T
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. teru_hideshima@dfci.harvard.edu
Anderson
Kenneth C
KC
D001854:Bone Marrow Cells / Q000187:drug effects; D002450:Cell Communication / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D036341:Intercellular Signaling Peptides and Proteins / Q000502:physiology; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D046988:Proteasome Endopeptidase Complex / Q000187:drug effects; D017154:Stromal Cells / Q000187:drug effects
D007155:Immunologic Factors; D036341:Intercellular Signaling Peptides and Proteins; D046988:Proteasome Endopeptidase Complex